OrbiMed Advisors LLC's Form 4 filing
Repare Therapeutics Inc. (RPTX) · filed Aug 30, 2021
- Accession no.
- 0000947871-21-000968
- Filed
- Aug 30, 2021, 6:37 PM ET
- Trade date
- Aug 26-30, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $615.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director |
| OrbiMed Capital LLCCIK 0001157524 | Director |
| OrbiMed Capital GP VII LLCCIK 0001760648 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2021 | Common Stock | SSaleDisposed | −4,157 | $34.52 | −$143,499.64 | 3,235,021 | Indirect | Duplicate filing |
| Aug 26, 2021 | Common Stock | SSaleDisposed | −126 | $34.52 | −$4,349.52 | 97,948 | Indirect | Duplicate filing |
| Aug 27, 2021 | Common Stock | SSaleDisposed | −6,884 | $33.94 | −$233,642.96 | 3,228,137 | Indirect | Duplicate filing |
| Aug 27, 2021 | Common Stock | SSaleDisposed | −209 | $33.94 | −$7,093.46 | 97,739 | Indirect | Duplicate filing |
| Aug 30, 2021 | Common Stock | SSaleDisposed | −6,500 | $33.92 | −$220,480 | 3,221,637 | Indirect | Duplicate filing |
| Aug 30, 2021 | Common Stock | SSaleDisposed | −197 | $33.92 | −$6,682.24 | 97,542 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.